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A sensitive, selective and high-throughput liquid chromatography–tandem mass spectrometry (LC–ESI–
MS/MS) method was developed and validated for the quantitation of tolvaptan in rabbit plasma. Sample
clean-up involved liquid–liquid extraction (LLE) and chromatography was performed on Zorbax SB C18
analytical column (50 mm2.1 mm, 3.5 mm) using 0.1% formic acid:methanol (20:80, v/v) as the mobile
phase. The parent-product ion transitions for the drug (m/z 449.2-252.1) and IS (m/z 456.2-259.2)
were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring
(MRM) and positive ion mode. The method was validated over the concentration range of 0.10–
1000.00 ng/mL and successfully applied to a pharmacokinetic study of healthy rabbits.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tolvaptan is especially useful for heart failure patients as they
have higher serum levels of vasopressin. Tolvaptan (INN), also
known as OPC-41061, is a selective, competitive vasopressin re-
ceptor 2 antagonist used to treat hyponatremia (low blood sodium
levels) associated with congestive heart failure, cirrhosis, and the
syndrome of inappropriate antidiuretic hormone (SIADH) [1].
Chemically it is (7)-4ʹ-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-
1H-1-benzazepin-1-yl) carbonyl]-otolu-m-toluidide. The empirical
formula is C26H25ClN2O3 and its molecular weight is 448.94 [2].
The pharmacokinetic properties of tolvaptan are stereospeciﬁc,
with a steady-state ratio of the S() to the R(þ) enantiomer
of about 3. The absolute bioavailability of tolvaptan is unknown.
At least 40% of the dose is absorbed as tolvaptan or metabolites.
Food does not affect the bioavailability of tolvaptan. Tolvaptan
is metabolized in the liver and its metabolites are inactive.
The pharmacokinetic parameters of tolvaptan in healthy subjects
were reported as follows: Tmax 2–4 h, Cmax 374 ng/mL, AUC024
3.71 μg h/mL, AUC(1) 4.55 μg h/mL, t1/2 12 h [3,4].
Literature retrieval revealed that there were few methods
reported for quantitation of tolvaptan in biological matrices [2,5–on and hosting by Elsevier B.V. All
University.
: þ91 8088259567.14]. As of now, to our knowledge, a few studies on tolvaptan
pharmacokinetics have been reported [2,5–14]. The LC–MS/MS
methods for determination of tolvaptan described in these pa-
pers have several obvious shortcomings. Firstly, the lower limit of
quantitations (LLOQs) in these reports were 0.457 [5], 2 [10], 5
[6–9,12,13] and 10 ng/mL [11], respectively. The low sensitivity
could not meet the requirement of the pharmacokinetic study of
low-dose tolvaptan. Secondly, the time-consuming and expensive
solid-phase extraction was used for pretreatment of samples in
these methods [2,6–13]. The PPT method was not suitable for
high throughput determination in pharmacokinetic study [5].
Thirdly, chromatography and validation details were not pro-
vided in these reports [2,6–13], which might have little guiding
signiﬁcance for reproducing or developing the determination
methods of tolvaptan. This was achieved by Pei et al., [5] and
Derangula et al. [14]. In this paper, we developed and validated a
highly sensitive, simple and speciﬁc LC–MS/MS method for de-
termination of tolvaptan in rabbit plasma using LLE for the ﬁrst
time. The method was successfully applied to a pharmacokinetic
study of tolvaptan in healthy rabbits.2. Experimental
2.1. Chemicals and materials
Reference standards of tolvaptan (99.7%) were obtained fromrights reserved. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Chemical structures of tolvaptan (A) and tolvaptan-D7 (B).
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was procured from United States of Pharmacopoeia (USP) (Fig. 1).
HPLC grade methanol and acetonitrile were obtained from Mal-
linckrodt Baker (Mexico). Reagent grade formic acid was obtained
from Merck Specialties Pvt. Ltd., (Mumbai, India). HPLC grade
methyl tertiary butyl ether and dichloromethane were obtained
from RCI Labscan (Mumbai, India). Water used in the entire ana-
lysis was prepared from the Milli-Q water puriﬁcation system
procured from Millipore (Bangalore, India). Rabbits were procured
from Bioneeds (Bangalore, India).
2.2. Instrumentation
The 1200 Series HPLC system (Agilent Technologies, Wald-
bronn, Germany) connected to the API 4200 triple quadrupole
mass spectrometer (ABI-SCIEX, Toronto, Canada) with a turbo-
electrospray interface in positive-ion mode was used for detection.
Data processing was performed on Analyst 1.5.1 software package
(SCIEX).
2.3. Standard stock, calibration standards and quality control sample
preparation
The standard stock solutions of 100.00 mg/mL of tolvaptan and
tolvaptan-D7 were prepared by dissolving a requisite amount in
methanol. Calibration standards and quality control (QC) samplesFig. 2. Parent ion mass spectrum (A) and pwere prepared with blank plasma from a standard stock solution
of tolvaptan. Calibration curve standards were made at con-
centrations of 0.10, 0.20, 0.50, 1.00, 10.00, 100.00, 200.00, 400.00,
600.00, 800.00 and 1000.00 ng/mL, while QC samples were pre-
pared at four levels, viz. 700.00 ng/mL (HQC, high quality control),
500.00 ng/mL (MQC, middle quality control), 0.30 ng/mL (LQC, low
quality control) and 0.10 ng/mL (LLOQC, lower limit of quality
control) for tolvaptan. From internal standard stock solution, IS
working solution of 100.00 ng/mL was prepared with 70% MeOH
in 0.1% formic acid and stored at 2–8 °C in the refrigerator. Cali-
bration standards and QC samples were stored at 30 °C until use.
2.4. Chromatographic conditions
Chromatographic separation was carried out on a reversed-
phase Zorbax SB C18 column (50 mm2.1 mm, 3.5 mm) using 0.1%
formic acid:methanol (20:80, v/v) as the mobile phase at a ﬂow-
rate of 0.6 mL/min at 40 °C. Retention time of tolvaptan and tol-
vaptan-D7 was found to be approximately 0.970.2 min with a
total runtime of 1.5 min.
2.5. Mass spectrometric conditions
Ionization and detection of the analyte and IS were carried out
on a triple quadrupole mass spectrometer, AB-SCIEX (Toronto,
Canada), equipped with electrospray ionization and operated in
positive ion mode. Quantitation was performed using multiple
reaction monitoring (MRM) mode to monitor parent-product ion
(m/z) transition for tolvaptan 449.2-252.1 (Fig. 2A and Fig. 2B).
For IS, the [MþH]þ (m/z 456.2) was monitored as the precursor
ion (Fig. 3A) and a fragment at m/z 259.2 was monitored as the
product ion (Fig. 3B). Mass parameters were optimized as source
temperature 600 °C, nebulizer gas 30 (nitrogen) psi, heater gas 40
(nitrogen) psi, curtain gas 25 (nitrogen) psi, CAD gas 7 (nitrogen)
psi, ion spray (IS) voltage 5500 V, source ﬂow rate 0.6 mL/min
without split, entrance potential 10 V, declustering potential 40 V,
and collision energy 16 V for both the analyte and IS, collision cell
exit potential 12 V and the dwell time 200 ms for the analyte androduct ion spectrum (B) of tolvaptan.
Fig. 3. Parent ion mass spectrum (A) and product ion spectrum (B) of tolvaptan-D7.
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2.6. Sample preparation
Prior to analysis, all frozen subject samples, calibration stan-
dards and QC samples were thawed and allowed to equilibrate at
room temperature. To an aliquot of 50 μL of spiked plasma sample,
50 μL of IS was added and vortexed brieﬂy. To these samples, 3 mL
of extraction solvent (methyl tertiary butyl ether:dichloromethane
(80:20) v/v) was added and capped and the samples were vor-
texed for 5 min. Centrifugation of the samples was done at
4000 rpm for 5 min at 20 °C. Supernatant from each sample was
transferred into respective tubes and evaporated to dryness under
nitrogen at 4072 °C. The dried samples were reconstituted with
500 μL of methanol: 0.1% formic acid (70:30, v/v). All the tubes
containing samples were vortexed brieﬂy and transferred into
autosampler vials for injection into the chromatographic system.
2.7. Method validation
The method validation was performed as per the United States
Food and Drug Administration (USFDA) guidelines [15]. The
method was validated for system suitability, carryover, linearity,
selectivity, precision and accuracy, sensitivity, matrix effect, re-
covery and stability.
2.7.1. System suitability and autosampler carryover
System suitability experiment was performed by using aqueous
solution of tolvaptan and IS at the start of each batch during the
method validation. The carryover effect of the autosampler was
evaluated by injecting a sequence of aqueous standard, mobile
phase, standard blank and extracted standard equivalent to the
highest standard in the calibration range. As per the acceptance
criteria, the response in the blank should not be greater than 20%
of LOQ response.
2.7.2. Linearity and LLOQ
The linearity of the method was determined by analysis of ﬁvelinear curves containing eleven non-zero concentrations. The ratio
of analyte to IS area versus analyte concentration was used for
regression analysis. Each calibration curve was analyzed in-
dividually by using least square weighted (1/x2) linear regression.
The lowest standard on the calibration curve was accepted as the
LOQ if the analyte response was at least ﬁve times more than that
of drug-free (blank) extracted plasma. The deviation of standards
other than LLOQ from the nominal concentration should not be
more than 715.0%. For LLOQ, it should not be more than 720.0%.
2.7.3. Precision and accuracy
For determining the intra-day accuracy and precision, replicate
analysis of plasma samples of tolvaptan was performed on the
same day. The run consisted of a calibration curve and six re-
plicates of LLOQC, LQC, MQC and HQC samples. The inter-day ac-
curacy and precision were assessed by analysis of ﬁve precision
and accuracy batches on four consecutive validation days. The
precision of the method was determined by calculating the per-
cent coefﬁcient of variation (%CV) for each level. The deviation at
each concentration level from the nominal concentration was ex-
pected to be within 715.0%, except LLOQ, for which it should be
within 720.0%.
2.7.4. Selectivity
The selectivity of the method towards endogenous plasma
matrix components was assessed in ten lots (ﬁve K2EDTA plasma
lots, two hemolyzed lots, two lipimic lots and one heparinised lot)
of blank rabbit plasma. This was done to estimate the extent to
which endogenous plasma components contribute towards inter-
ference at the retention time of the analytes and IS. The cross talk
of MRM for analyte and IS was checked using the highest standard
on the calibration curve and working solution of IS (Fig. 4).
2.7.5. Matrix effect
Ion suppression/enhancement effects on the MRM LC–MS/MS
sensitivity were evaluated by the post-column analyte infusion
experiment. A standard solution containing tolvaptan (at MQC
level) and IS was infused post-column into the mobile phase at
Fig. 4. (A) Blank, (B) Blankþ IS, and (C) LLOQ chromatograms of tolvaptan and tolvaptan-D7 in rabbit plasma.
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10 μL of extracted control plasma were then injected into the
column by the autosampler, and MRM LC–MS/MS chromatogram
was acquired for the analytes and IS. Any dip in the baseline upon
injection of double blank plasma (without IS) would indicate ion
suppression, while a peak at the retention time of the analyte and
IS indicates ion enhancement.2.7.6. Recovery
The relative recovery (RE) and process efﬁciency were as-
sessed; all three parameters were evaluated at HQC, MQC and LQC
levels in six replicates.
RE was calculated by comparing the mean area response of
extracted samples (spiked before extraction) to that of un-ex-
tracted samples (spiked after extraction) at each QC level. The
recovery of IS was similarly estimated.
The overall ‘process efﬁciency’ (PE) was calculated as
(MERE)/100. The assessment of relative matrix effect was based
on the direct comparison of the MS/MS responses (peak areas) of
the analytes spiked into extracts originating from different lots of
plasma. The variability in these responses, expressed as CV (%),
was considered as the measurement of relative matrix effect.
Absolute matrix effect (ME) was assessed by comparing the
mean area response of un-extracted samples (spiked after ex-
traction) with that of neat standard solutions.2.7.7. Stability
Stability experiments were carried out to examine the analyte
stability in stock solutions and in plasma samples under different
conditions. Short-term stability at room temperature and long-
term stability of spiked solution stored at 30 °C were assessed by
comparing the area response of stability sample of the analyte and
IS with that of sample prepared from fresh stock solutions. The
solutions were considered stable if the deviation from nominal
value was within 710%.
Autosampler (wet extract) stability, bench top stability, freeze–
thaw stability and long-term stability were performed at LQC and
HQC levels in six replicates at each level. The samples were con-
sidered stable if the deviation from the mean calculated con-
centration of freshly thawed QC samples was within 715%.
2.8. Analysis of plasma samples
The bio-analytical method described above was used to de-
termine tolvaptan concentrations in plasma followed by oral ad-
ministration to healthy rabbits. Six New Zealand albino male
rabbits weighing between 1.5 and 1.8 kg were kept in individual
cages and maintained at 25 °C for 10 days prior to experiment.
Standard diet and water ad libitum were given to them. All ex-
periments were performed according to the guidelines of the In-
stitutional Animal Ethics Committee, Bioneeds Bangalore. Tolvap-
tan, 2.77 mg/1.8 kg body weight (equivalent dose of 30 mg tol-
vaptan tablet), was administered orally in a single dose. All studies
K.S. Moola et al. / Journal of Pharmaceutical Analysis 5 (2015) 371–377 375were performed after keeping rabbits for overnight fasting. Blood
samples of 0.3 mL were collected at the interval 0 (pre-dose)
0.333, 0.667, 1.333, 2.667, 3, 3.333, 3.67, 4.5, 8, 16, 30, 36, 42 and
48 h (post-dose) in heparinized Eppendorf tubes. These samples
were centrifuged immediately at 3500 rpm and 4 °C temperature
for 10 min. Plasma samples were taken and stored at 30 °C until
assay. Pharmacokinetic parameters like peak plasma concentration
(Cmax), time to reach peak plasma concentration (Tmax), area under
the concentration–time curve (AUC) and elimination half-life (t1/2)
were calculated by a non-compartmental statistic model using
Win Non-Lin 5.1 software (Pharsight, USA).
2.9. Pharmacokinetics and statistical analysis
Blood samples were taken for a period of 3–5 times of the
terminal elimination half-life (t1/2) and it was considered as the
area under the concentration–time curve (AUC) ratio higher than
80% as per the FDA guidelines. Plasma tolvaptan concentration–
time proﬁles were visually inspected, and Cmax and Tmax values
were determined. The AUC0–t was obtained by the trapezoidal
method. The AUC0–1 was calculated up to the last measureable
concentration, and extrapolations were obtained using the last
measureable concentration and the terminal elimination rate
constant (Ke) was estimated from the slope of the terminal ex-
ponential phase of the plasma of the tolvaptan concentration–time
curve (by means of the linear regression method). The terminal
elimination half-life (t1/2) was then calculated as 0.693/Ke. The
pharmacokinetic parameters were considered when the ratio of
averages of log transformed data was within 80%–125% for AUC0–t,
AUC0–1 and Cmax [16–18].3. Results and discussion
3.1. Method development
During method development, different options were evaluated
to optimize mass spectrometry detection parameters, chromato-
graphy and sample extraction.
3.1.1. Mass spectrometry detection parameters optimization
Electrospray ionization (ESI) provided a maximum response
over atmospheric pressure chemical ionization (APCI) mode and
was chosen for this method. The instrument was optimized to
obtain sensitivity and signal stability during infusion of the analyte
in the continuous ﬂow of mobile phase to electrospray ion source
operated at both polarities at a ﬂow rate of 10 μL/min. Tolvaptan
gave more responses in positive ion mode as compared to the
negative ion mode. The predominant peaks in the primary ESI
spectra of tolvaptan and tolvaptan-D7 correspond to the [MþH]þ
ions atm/z 449.2 and 456.2, respectively [Figs. 2A and 3A]. Product
ions of tolvaptan and tolvaptan-D7 were m/z of 252.1 and 259.2,
respectively [Figs. 2B and 3B].
3.1.2. Chromatography optimization
Initially, a mobile phase consisting of ammonium formate and
methanol in varying combinations was tried, but a low response
was observed. The mobile phase containing ammonium acetate:
acetonitrile (20:80, v/v) gave the better response, but poor peak
shape was observed. A mobile phase with various strengths of
formic acid in water in combination with methanol and acetoni-
trile with varying combinations was tried. Using a mobile phase
containing 0.1% formic acid in water in combination with metha-
nol (20:80, v/v), the best signal along with a marked improvement
in the peak shape was observed for tolvaptan and tolvaptan-D7.
Short length columns such as Symmetry Shield RP18(50 mm2.1 mm, 3.5 μm), Inertsil ODS-2V (50 mm4.6 mm,
5 μm), Hypurity C18 (50 mm4.6 mm, 5 μm) and Hypurity Ad-
vance (50 mm4.0 mm, 5 μm) were tried during the method
development. Symmetry Shield RP18 column gave a relatively good
peak shape, but the response was low. Using Hypurity C18 column,
poor chromatography was observed. The best signal was obtained
using the Zorbax SB C18 (50 mm2.1 mm, 3.5 mm) column. It gave
satisfactory peak shapes for both tolvaptan and tolvaptan-D7. Flow
rate of the mobile phase was adjusted and optimized at 0.6 mL/
min without splitter. Both the drug and IS were eluted at 0.9 min
with the total run time of 1.5 min. For an LC–MS/MS analysis,
utilization of stable isotope-labeled or suitable analog drugs as an
internal standard proved helpful when a signiﬁcant matrix effect
was possible. In our case, tolvaptan-D7 was found to be best for
the present purpose. The column oven temperature was kept at a
constant temperature of about 40 °C. Injection volume of 10 mL
sample was adjusted for better ionization and chromatography.
3.1.3. Extraction optimization
Prior to loading the sample for LC injection, the co-extracted
proteins should be removed from the prepared solution. For this
purpose, we initially tested different extraction procedures like
protein precipitation (PP), liquid–liquid extraction (LLE), and solid
phase extraction(SPE). We found ion suppression effect in PP
method for the drug and IS. Further, we tried with SPE and LLE and
found that LLE was suitable for extraction of the drug and IS. We
tried several organic solvents (ethyl acetate, chloroform, n-hexane,
dichloromethane and methyl tertiary butyl ether) individually as
well with combinations in LLE to extract the analyte from the
plasma sample. In our case, the methyl tertiary butyl ether:di-
chloromethane (80:20, v/v) combination served as a good ex-
traction solvent. High recovery and selectivity were observed in
the LLE method. These optimized detection parameters, chroma-
tographic conditions and extraction procedure resulted in reduced
analysis time with accurate and precise detection of tolvaptan in
rabbit plasma.
3.2. Method validation
The method was validated in terms of system suitability, car-
ryover, linearity, selectivity, precision and accuracy, sensitivity,
matrix effect, recovery, stability, ruggedness and dilution integrity.
3.2.1. System suitability and autosampler carryover
Throughout the method validation, the CV of the system suit-
ability was observed below 5.0% at the retention time of tolvaptan
and IS. Carryover evaluation was performed in each analytical run
to ensure that it did not affect the accuracy and precision of the
proposed method. There was a negligible carryover (r5% of the
LLOQ response) observed during autosampler carryover experi-
ment. No enhancement in the response was observed in double
blank after subsequent injection of the highest calibration stan-
dard (aqueous and extracted) at the retention time of the analyte
and IS.
3.2.2. Linearity and LLOQ
The calibration curves were linear over the concentration range
of 0.10–1000.00 ng/mL with the correlation coefﬁcient rZ0.9850
for tolvaptan (Table1).
3.2.3. Precision and accuracy
The accuracy and precision (%CV) observed for the calibration
curve standards ranged from 96.83% to 112.80% and 0.95% to
13.91% for tolvaptan. The lowest concentration (LLOQ) in the
standard curve for tolvaptan was measured at a signal-to-noise
ratio (S/N) of Z20. The intra- and inter-batch precision and
Table 1
Calibration curve details.
Spiked concentration
(ng/mL)
Mean found7SD
(ng/mL)
CV (%) Accuracy (%)
0.1 0.1170.00 2.73 105.40
0.2 0.2270.03 13.19 109.30
0.5 0.5670.03 5.96 112.80
1 1.0570.05 4.38 105.20
10 10.1770.23 2.21 101.72
100 100.3871.98 1.97 100.38
200 193.6776.71 3.46 96.83
400 390.3373.98 1.02 97.58
600 601.00716.40 2.73 100.17
800 800.6777.60 0.95 100.08
1000 1004.33712.17 1.21 100.43
Table 3
Stability of tolvaptan in rabbit plasma samples.
Stability Plasma con-
centration
(ng/mL)
Concentration
measured (mean
found7SD)
(n¼6; ng/mL)
CV (%)
(n¼6)
Accuracy (%)
Room tempera-
ture stability
(24 h)
0.30 0.3470.02 5.94 113.11
700.00 690.00728.79 4.17 98.57
Autosampler
stability (72 h)
0.30 0.3170.01 4.44 104.72
700.00 675.00713.98 2.07 96.43
Freeze–thaw
stability (3
cycles)
0.30 0.3270.02 7.67 107.61
700.00 674.44717.63 2.61 96.35
Long term stabi-
lity (65 days)
0.30 0.3270.03 10.18 105.44
700.00 724.17728.22 3.90 103.45
K.S. Moola et al. / Journal of Pharmaceutical Analysis 5 (2015) 371–377376accuracy were established from validation runs performed at HQC,
MQC, LQC and LLOQ QC levels. The intra- and inter-batch precision
ranged from 2.12% to 7.76% and 1.17% to 9.19%, respectively, for
tolvaptan. The accuracy values were within 97.43%–113.33% and
97.05%–114.60% for the analyte in intra- and inter-batches
(Table 2).
3.2.4. Selectivity
To establish the selectivity of the method for interference due
to endogenous plasma components from haemolysed, lipidemic,
heparinised and K2EDTA blank plasmas, the % change in the area
ratio (analyte/IS) at LLOQ level was within 4%–6%, while the pre-
cision (%CV) in their measurement varied from 2.0% to 4.5%.
The extraction procedure together with mass detection gave
very good selectivity for the analysis of the drug and IS in the
blank plasma. No endogenous interferences were found at the
retention times of the analyte and IS.
3.2.5. Matrix effect
Matrix effect may be deﬁned as a composite of some undesir-
able effects that originate from a biological matrix. These com-
ponents may result in ion-suppression/ion-enhancement, de-
crease/increase in sensitivity of analytes over a period of time,
increased baseline, imprecision of data, drift in retention time and
distortion or tailing of a chromatographic output. The result of a
post-column infusion experiment indicated no ion suppression or
enhancement at the retention time of the analyte and IS as evident
from the ﬂat baseline. There was no ion suppression and en-
hancement observed at retention time of the analyte and IS.
3.2.6. Recovery
The relative recovery and process efﬁciency for the drug was
87.10%. The recovery for IS in rabbit plasma was 90.37%.
3.2.7. Stability
Stock solution stability was performed to check stability of
tolvaptan and tolvaptan-D7 in stock solutions prepared in me-
thanol and stored at 2–8 °C in a refrigerator. The freshly preparedTable 2
Precision and accuracy (analysis with spiked plasma samples at four different concentr
Nominal concentration (ng/mL) Intra-run (n¼6)
Mean found7SD (ng/mL) CV(%)
0.10 0.1170.01 7.76
0.30 0.3470.03 7.50
500.00 495.33712.55 2.53
700.00 682.00714.45 2.12stock solutions were compared with stock solutions prepared
before 9 days. The % change for tolvaptan and tolvaptan-D7 were
both less than 5%, indicating that stock solutions were stable at
least for 9 days.
Bench top and autosampler stability for tolvaptan was in-
vestigated at LQC and HQC levels. The results revealed that tol-
vaptan was stable in plasma for at least 24 h at room temperature
and 72 h in an autosampler. It was conﬁrmed that repeated
freezing and thawing (three cycles) of plasma samples spiked with
tolvaptan at LQC and HQC levels did not affect their stability. The
long-term stability results also indicated that tolvaptan was stable
in a matrix up to 65 days at 30 °C (Table 3).
3.3. Application of the method
The above validated method was used in the determination of
tolvaptan in plasma samples for establishing the pharmacokinetics
of a single 2.77 mg/1.8 kg body weight (equivalent dose to 30 mg
tablet) in 12 healthy rabbits by oral route. Typical plasma con-
centration versus time proﬁles is shown in Fig. 5. All the plasma
concentrations of tolvaptan were within the standard curve region
and retained above 0.1 ng/mL (LOQ) for the entire sampling period
(Table 4).4. Conclusion
The proposed method exhibited excellent performance in
terms of sensitivity, selectivity, ruggedness and efﬁciency (1.5 min
per sample) due to cleaner extracts, with simplicity of sample
preparation. This method was successfully applied to pharmaco-
kinetics of rabbit plasma.Acknowledgments
The authors are grateful to the Indian Institute of Chemicalations).
Inter-run (n¼36)
Accuracy
(%)
Mean found7 SD (ng/mL) CV(%) Accuracy
(%)
111.40 0.1170.01 9.19 114.60
113.33 0.3270.02 7.62 105.33
99.07 488.00713.25 2.71 97.60
97.43 679.3377.96 1.17 97.05
Table 4
Mean pharmacokinetic parameters of tolvaptan in rabbit plasma after oral
administration of 2.77 mg/1.8 kg in male rabbits.
Pharmacokinetic parameter Values
AUC0t (ng h/mL) 2819.70
Cmax (ng/mL) 270.50
AUC0-1 (ng h/mL) 2870.96
Kel 0.07821
Tmax (h) 3.33
t1/2 8.86
ct 4.009
Ct/Kel 51.26
AUC01: area under the curve extrapolated to inﬁnity;
AUC0 t: area under the curve up to the last sampling time;
Cmax: the maximum plasma concentration;
Tmax: the time to reach peak concentration; and
Kel: the apparent elimination rate constant.
Fig. 5. Mean plasma concentrations vs. time graph of tolvaptan after oral admin-
istration of 2.77 mg/1.8 kg in male rabbits.
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